Trial Profile

Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of AB-1002 in Subjects With NYHA Class III Heart Failure

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 1002 (Primary)
Indications Heart failure
Focus First in man; Therapeutic Use
Sponsors Asklepios BioPharmaceutical

Most Recent Events

07 May 2026 According to an Asklepios Biopharmaceutical media release, data from the trial will be presented at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, which takes place May 11-15, 2026, in Boston, Massachusetts, USA.
21 Oct 2025 According to an Asklepios Biopharmaceutical media release, data from this trial published in peer-reviewed journal Nature Medicine
21 Oct 2025 Results published in the Asklepios Biopharmaceutical Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com